中文摘要：

目的：观察芪扶正胶囊在卵巢癌化疗并发症预防中的效果。方法：纳入2014年1月至2015年3月我院收治的卵巢癌患者73例,按随机数字表法分为观察组36例和对照组37例,对照组患者术后给予常规化疗药物进行治疗,观察组患者在对照组化疗基础上加用贞芪扶正胶囊治疗,记录并分析治疗后两组患者癌抗原125、人附睾分泌蛋白4、腹水深度、卡式评分（KPS评分）、肿瘤病人生活质量评分（QOL评分）、血红蛋白（HGB）、血小板（PLT）和白细胞（WBC）、谷丙转氨酶（ALT）和总胆红素（TBIL）水平变化、治疗疗效以及不良反应发生率。结果：观察组化疗后癌抗原125水平为（56.4±10.3）IU/ml,明显低于对照组（83.7±15.7）IU/ml;观察组化疗后人附睾分泌蛋白4为（162.9±60.1）pmol/L,明显低于对照组（284.6±80.5）pmol/L;观察组化疗后腹水深度为（2.13±0.42）cm,明显低于对照组（3.26±0.72）cm;4观察组化疗后KPS评分和QOL评分分别为（88.62±5.68、44.18±4.45）分,均明显高于对照组（80.67±5.16、36.91±4.22）分;5治疗后观察组化疗后并发症比例为16.67%,明显低于对照组37.84%;6治疗后观察组HGB下降、PLT下降、WBC下降比例均明显低于对照组。结论：贞芪扶正胶囊在卵巢癌化疗中可提高癌症病人的生活质量并且降低化疗过程中的不良反应发生率。

英文摘要：

Objective： To observe the clinical effect of the prevention of ovarian cancer chemotherapy complications with Zhenqifuzheng capsule. Methods： 73 patients from January 2014 to March 2015 ,were randomly divided into 37 cases of the control group patients after 36 cases of the observation group and the control group received conventional chemotherapy treatment observed in patients with Zhenqifuzheng capsule chemotherapy treatment on the basis of the control group, recorded and analyzed two groups of patients after treatment of cancer antigen 125, secreted human epididymis protein 4, ascites depth, score card （ KPS score）, cancer patients quality of life score （ QOL score）, therapeutic efficacy and incidence of adverse reactions. Results： ①After chemotherapy, CA125 levels of observation group was（ 56.4 ± 10.3 ） IU / ml, lower than the control group （ 83.7 ± 15.7） IU / ml, and the difference was significant （ P 〈 0.05 ） ; ②After chemotherapy, HFA level of the observation group was （ 162.9 ± 60.1） pmol / L, lower than the control group （284.6 ± 80.5 ） pmol / L, and the difference was significant （ P 〈 0.05 ） ; ③After chemotherapy, ascites depth of the observation group was （2.13 ± 0.42） cm, lower than the control group （ 3.26 ± 0.72） cm, and the difference was significant （ P 〈 0.05） ; ④After chemotherapy, KPS score and QOL score respectively （88.62 ± 5.68, 44.18 ± 4.45） points were higher （80.67 ± 5.16, 36.91 ± 4.22） points, and the difference was significant （ P 〈 0.05 ） ; ⑤After chemotherapy, complications of observation group was 16.67%, lower than the control group 37.84% , the difference was compared between the two groups was significant （ P 〈 0.05 ）. ⑥The decreased hemoglobin, thrombocytopenia, leukopenia ratio of observation group was lower than the control group, and compared the difference between having a significant （ P 〈 0.05 ）. Conclusions ： Zhenqifuzheng capsule in ovarian cancer chemotherapy can re